IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies.
about
Patient-derived xenograft models of colorectal cancer in pre-clinical research: a systematic reviewGenetically engineered mouse models in oncology research and cancer medicinePhase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.STAT3-mediated IGF-2 secretion in the tumour microenvironment elicits innate resistance to anti-IGF-1R antibodyIn vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer.Correlation Between IGFs-Related Proteins Expression and Incidence of Colorectal Cancer in Diabetic Patients and Related Mechanisms.Immunomediated Pan-cancer Regulation Networks are Dominant Fingerprints After Treatment of Cell Lines with Demethylation.The genomic landscape of response to EGFR blockade in colorectal cancer.Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors.A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors.Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells.Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination StudiesRationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2.Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer.The changing paradigm of tumour response to irradiation.Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer.Impact of IGF-1, IGF-1R, and IGFBP-3 promoter methylation on the risk and prognosis of esophageal carcinoma.Insulin Receptor Isoforms in Physiology and Disease: An Updated View.Stromal-derived IGF2 promotes colon cancer progression via paracrine and autocrine mechanisms.Molecular characterization of colorectal adenomas with and without malignancy reveals distinguishing genome, transcriptome and methylome alterations.Preclinical mouse solid tumour models: status quo, challenges and perspectives.Essential Role of DNA Methyltransferase 1-mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors.Overproduction of IGF-2 drives a subset of colorectal cancer cells, which specifically respond to an anti-IGF therapeutic antibody and combination therapies.Strategy to targeting the immune resistance and novel therapy in colorectal cancer.Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts.Colorectal cancer. Combining drug therapies to improve treatment efficacy in metastatic colorectal cancer.Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathwayMouse models in the era of large human tumour sequencing studies
P2860
Q26741651-B4C8906A-7820-41BC-A778-7E9F703AF50DQ28079323-D8558CED-3F42-4D10-8896-2C353936F4BDQ33275887-6E8B9408-A5F9-42E2-AD6B-C9FBA5CCC742Q36169762-4B991ACF-57A5-4EA3-A400-37F261178E9BQ36310845-61D4AF76-1403-4DBE-9053-AA54772BA93AQ36695304-7E3CCCD6-5212-4F65-982A-2109600DEDDAQ36848243-97292D72-D639-4925-BB78-82B403B66B9EQ36930106-542D272F-9405-4050-8DAF-0D309DDA7377Q37642614-7D0932AF-E18A-4757-96D4-2027C3662D6CQ37687796-707F193B-0B92-4CEB-B29A-9ECA3F228C51Q37706176-09366ACD-0511-4AA1-ABEA-A0C8576223F1Q38641329-E59FFE81-47D7-49E0-91C0-F30ED747388FQ38803202-7CAB6E8F-8367-4321-8970-0216E67AE098Q38805790-FBFB2926-0F89-45D2-AFA8-E4F85FAE02B4Q38896870-BA4D1236-AB00-4EFF-B9D7-77C115706B00Q40953655-4CDE1FEF-9EF9-48E5-893E-46CFFE72D7B1Q41054651-94147952-F364-40CD-A69C-33EA1D663B3BQ47668280-CF02B58D-1EC6-4FE3-9D16-A869CE218F58Q48112414-F8E8F12C-540E-4261-B8FF-8CD542088DEBQ49912428-9236B9BD-A14E-4D3B-B986-9BB47082233AQ50096902-71CB4FA4-4321-4730-811F-5477E0BF2D71Q51176745-796A8415-A006-4863-B9AD-9835AF365C63Q51650705-30244017-3936-49F7-9D1A-2F6F49F30E34Q52320729-20464CA5-7F90-4E09-80CF-6FE3D09D6120Q52638232-31B8EA9C-41CD-44C4-9C03-6A9FF7AB111BQ54289925-E9AAD421-E4E2-4915-9E6F-11B263E72EA2Q58735770-B1312B37-16B0-4B1B-913A-3110284C4C86Q58776633-697DFD5F-7268-4710-8E0B-D7D1A74A9D0E
P2860
IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
IGF2 is an actionable target t ...... sponse to anti-EGFR therapies.
@en
type
label
IGF2 is an actionable target t ...... sponse to anti-EGFR therapies.
@en
prefLabel
IGF2 is an actionable target t ...... sponse to anti-EGFR therapies.
@en
P2093
P2860
P50
P1476
IGF2 is an actionable target t ...... esponse to anti-EGFR therapies
@en
P2093
Andrea Bertotti
Barbara Lupo
Eva Budinská
Jessica Erriquez
Livio Trusolino
Sabine Tejpar
P2860
P304
P356
10.1126/SCITRANSLMED.3010445
P407
P50
P577
2015-01-01T00:00:00Z